Pulse Biosciences Reports Third Quarter 2022 Financial Results
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company and creator of the unique CellFX® System which harnesses and effectively controls the application of Nano-Pulse Stimulation™ (NPS™) to human cells and tissue for ablation in multiple therapeutic conditions, today announced financial results for the third quarter ended September 30, 2022
By AP News
Published - Nov 10, 2022, 04:08 PM ET
Last Updated - Mar 22, 2024, 01:38 PM EDT
HAYWARD, Calif.--(BUSINESS WIRE)--Nov 10, 2022--
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company and creator of the unique CellFX® System which harnesses and effectively controls the application of Nano-Pulse Stimulation™ (NPS™) to human cells and tissue for ablation in multiple therapeutic conditions, today announced financial results for the third quarter ended September 30, 2022.
Company Updates